Dietary Supplementation on Fat Oxidation
The purpose of this pilot study is to evaluate the effects of 4 weeks of daily consumption of encapsulated N-trans-caffeoyl tyramine (NCT) and N-trans-feruloyl tyramine (NFT) at a dose of 120 mg/d on measures of fat oxidation in women with overweight or obesity. The hypothesis is that fat oxidation at rest (measured vi
| Condition(s) | Overweight, Obesity |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The purpose of this pilot study is to evaluate the effects of 4 weeks of daily consumption of encapsulated N-trans-caffeoyl tyramine (NCT) and N-trans-feruloyl tyramine (NFT) at a dose of 120 mg/d on measures of fat oxidation in women with overweight or obesity. The hypothesis is that fat oxidation at rest (measured via indirect calorimetry) and over a 24 h period (measured via d31-palmitic acid stable isotope tracer) will be higher in the group receiving the active study product compared to the control product at the end of the 4-week consumption period. |
| Who can participate | Inclusion Criteria 1. Female, ≥18 and \<50 years of age at visit 1 (day -28). 2. Body mass index (BMI) of ≥29.0 kg/m2 to \<40.0 kg/m2 at visit 1 (day -28). 3. No health conditions that would prevent fulfilling the study requirements as judged by the Investigator on the basis of medical history. 4. History of regular menstrual cycles with menses (21-35 d per cycle) for at least 3 months prior to visit 1 (day -28). 5. Stable use of non-weight loss (e.g., semaglutide) prescription medications allowed, where stable use is defined as the same class of medication and dose for at least 90 d prior to visit 1 (day -28). 6. Willing to discontinue any dietary supplement use (except for conventional once daily vitamin/mineral supplement\[s\]), for one week prior to visit 2 and throughout the study. 7. |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Lead sponsor | Brightseed |
| Locations | Addison, Illinois, United States |
| Start date | 2024-07-31 |
| NCT ID | NCT06548048 |
| Official listing | https://clinicaltrials.gov/study/NCT06548048 |